HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
종목 코드 HSCSW
회사 이름HeartSciences Inc
상장일Jun 15, 2022
CEOMr. Andrew Simpson
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소550 Reserve St, Suite 360
도시SOUTHLAKE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호76092
전화16822377781
웹사이트https://heartsciences.com/
종목 코드 HSCSW
상장일Jun 15, 2022
CEOMr. Andrew Simpson
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음